Van Hauwermeiren Timothy reported grant involving 19,226 derivative units of Denali Therapeutics Inc. at $0.00 for $0 on Jun 3, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Jun 5, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
19,226Stock Option (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
19,226Direct
Trade date
Jun 3, 2026Grant
Filed
Jun 5, 2026, 4:44 PM ET2-day reporting delay
Accession
0001816206-26-000003Code A · Transaction 98804
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Related trades are temporarily unavailable. Open the SEC filing for the complete report, or reload this page.

DNLI price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
DNLI · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −4.4%1w ago +3.5%1d ago −0.9%
Returns since7d +11%30d +32%90d180d1y

Footnotes in full

F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2: Includes 17,040 unvested RSUs. F3: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.